JAK2 and gastric neoplasm: To test the idea of dual blockade of JAK2 and STAT3 activation in the stomach and subsequent gastric cancer development, we have used both in vitro and in vivo approaches to assess whether WP1066 can slow or block gastric tumour growth through inhibition of JAK2/STAT3 activity, and other closely related oncogenic signalling pathways.